Opendata, web and dolomites

BraINstorm SIGNED

Engineered nanocarriers for simultaneous anticancer immune response and “switching” of tumor-associated macrophages for intranasal glioblastoma treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BraINstorm project word cloud

Explore the words cloud of the BraINstorm project. It provides you a very rough idea of what is the project "BraINstorm" about.

m2    lasting    microenvironment    50    drug    model    switch    effect    acid    re    oligonucleotide    education    treat    taas    followed    tumoral    emerged    regards    precludes    standard    local    peptides    reduces    patient    mucosa    conventional    promotes    performed    cpg    advantage    intranasal    administration    tackle    adhesivity    antigen    care    engineer    complexity    oligonucleotides    invasiveness    blood    conjugates    macrophage    intrinsic    survival    crossing    therapeutic    strategy    tam    prophylactic    surgery    ex    immunotherapeutic    combination    nasal    m1    radiotherapy    stimulation    clinically    treatment    anticancer    storm    therapies    explore    biocompatibility    gbm    immunotherapy    cells    brainstorm    preliminary    curable    rate    cancer    anti    vivo    types    infiltrated    route    expansion    resection    assessing    immunomodulatory    barrier    muco    size    physical    hyaluronic    parallel       brain    chemical    explored    chemotherapy    glioblastoma    macrophages    disease    memory    invasive    comprise    release    appealing    immunoconjugates    immune    generating    turning    nose    position    tumor    vitro   

Project "BraINstorm" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE CATHOLIQUE DE LOUVAIN 

Organization address
address: PLACE DE L UNIVERSITE 1
city: LOUVAIN LA NEUVE
postcode: 1348
website: www.uclouvain.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 166˙320 €
 EC max contribution 166˙320 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) coordinator 166˙320.00

Map

 Project objective

Glioblastoma (GBM) remains a non-curable disease due to its high complexity and its position beyond the blood-brain barrier, which precludes access by conventional therapies. The current standard of care includes tumor resection surgery followed by radiotherapy or chemotherapy; an invasive process with a survival rate after five years is less than 5%. Tumor-associated macrophages (TAM) type 2 (M2 macrophages) comprise 30-50% of the infiltrated cells in GBM microenvironment and support tumor expansion. Immunotherapy represents an appealing strategy to treat several cancer types by turning the immune system against tumor cells; tumor antigen peptides (TAAs) recently emerged as an immunotherapeutic approach that can provide for a long-lasting immune response. Immunomodulatory oligonucleotides can “switch” M2 macrophages into M1 macrophages that produce an anti-tumoral effect. The BraINstorm (Brain INtranasal storm) project aims to engineer a hyaluronic acid (HA)-based combination conjugates that tackle GBM by the stimulation of the immune system via the delivery of TAAs and an immunomodulatory oligonucleotide (CpG) that promotes M2 macrophage “re-education” generating an “anticancer storm”. In parallel, taking advantage of the intrinsic muco-adhesivity of HA, BraINstorm will explore the nose-to-brain drug delivery, a more patient-friendly route that reduces the invasiveness. Novel combination immunoconjugates will be fully chemical-physical characterized and preliminary in vitro studies will be performed assessing the biocompatibility, drug release, and nasal mucosa barrier crossing in an ex-vivo model. Finally, the prophylactic and therapeutic activity of the HA-based conjugates will be in vivo explored in a clinically relevant GBM in vivo model through intranasal (IN) and local treatment administration with regards to effects on tumor size, immune memory, and survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINSTORM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRAINSTORM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GLIOHAB (2019)

Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation

Read More  

UNITE (2019)

Unification Through Law: The Court of Justice of the European Union as Cultural-Moral Agent

Read More  

PreSpeech (2018)

Predicting speech: what and when does the brain predict during language comprehension?

Read More